Please login to the form below

natalizumab

This page shows the latest natalizumab news and features for those working in and with pharma, biotech and healthcare.

Despite the setback, Novartis is continuing to expand its generics division, with natalizumab its fifth proposed biosimilar in nine months.

Roche sets disruptive price for new MS drug Ocrevus in US

remitting form, where Ocrevus' twice-yearly dosing gives it an advantage over other injectable MS therapies such as Biogen's Tysabri (natalizumab) and Zinbryta (daclizumab).
Neurodegenerative disorders market set to reach $45bn by 2022

for Biogen's Tysabri (natalizumab) and Novartis' Gilenya (fingolimod).
Novartis drug works in secondary progressive MS

After years of disappointing trials in SPMS - most recently the failure of Biogen's Tysabri (natalizumab) - there are finally some optimistic signs that patients with progressive forms of MS could get
Biogen cuts workforce and culls pipeline projects

Among the pipeline casualties are Tecfidera for secondary progressive MS, and Biogen also reported yesterday that its injectable MS drug Tysabri (natalizumab) was unable to slow disability progression in this
Pfizer maintains lead in top CNS drug sales - just

Biogen's rise is predominately due to its growing share of the multiple sclerosis (MS) market, with strong sales for its established medicine Tsyabri(natalizumab) and more recent launches of two

More from news
Approximately 4 fully matching, plus 48 partially matching documents found.

Deal Watch February 2017

The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... 17, 900. Perrigo/ Royalty Pharma. Tysabri
Pharma deals during February 2013

Deal of the month. The largest agreed deal announced was Biogen Idec's acquisition of Elan's interest in Tysabri (natalizumab), the multiple sclerosis (MS) treatment, thereby terminating their previous collaboration

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Michael Fleming joins biosimilars firm Coherus

Fleming was most recently at Elan where he was head of commercial and of the company's Tysabri (natalizumab) franchise.
XenoPort appoints chief medical officer

He joined XenoPort from Biogen Idec where he was joint programme team leader for the hugely successful multiple sclerosis (MS) treatment Tysabri (natalizumab) helping with drug's launches in markets that

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Add my company

Improve clinical trials through patient journey mapping: Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...